Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More

by Zacks Equity Research

Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.

Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate

by Zacks Equity Research

Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.

Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam

by Zacks Equity Research

Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.

Ekta Bagri headshot

Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA

by Ekta Bagri

Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.

Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval

by Zacks Equity Research

Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.

Biogen Inc. (BIIB) Stock Moves -0.57%: What You Should Know

by Zacks Equity Research

In the latest trading session, Biogen Inc. (BIIB) closed at $298.49, marking a -0.57% move from the previous day.

Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.

Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study

by Zacks Equity Research

Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Biogen Inc. (BIIB) closed at $295.95, marking a -1.98% move from the previous day.

DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study

by Zacks Equity Research

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.

Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down

by Zacks Equity Research

Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.

INmune (INMB) Announces Positive Data for its AD Candidate

by Zacks Equity Research

INmune Bio (INMB) announces positive data for its AD candidate, XPro, from an early stage study. Shares are up in pre-market.

3 Large Biotech Stocks Worth Adding to Your Portfolio

by Zacks Equity Research

REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $338.24 in the latest trading session, marking a -0.2% move from the prior day.

AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study

by Zacks Equity Research

AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%

Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval

by Zacks Equity Research

Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.

Cassava (SAVA) Down as Quanterix Issues Statement on AD Study

by Zacks Equity Research

Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.

Biogen Inc. (BIIB) Stock Moves -0.15%: What You Should Know

by Zacks Equity Research

Biogen Inc. (BIIB) closed at $342.24 in the latest trading session, marking a -0.15% move from the prior day.

Cassava (SAVA) Responds to Charges Against its Integrity in AD Study

by Zacks Equity Research

Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.

Kinjel Shah headshot

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)

by Kinjel Shah

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Kinjel Shah headshot

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On

by Kinjel Shah

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Mark Vickery headshot

Delta Variant Catches Up with the Stock Market

by Mark Vickery

Today, worries about growth and demand, at least partially caused by the Delta variant of Covid-19 manifesting in pockets of America.

Here is Why Prothena (PRTA) is Up More Than 155% in Three Months

by Zacks Equity Research

Prothena (PRTA) surges substantially in the past three months on solid prospects of its AD candidates following Biogen???s AD drug approval.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q2 Earnings Releases?

by Sweta Jaiswal, FRM

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.